FDAnews
www.fdanews.com/articles/171029-medtronics-stent-graft-system-demonstrates-efficacy-in-global-registry

Medtronic’s Stent Graft System Demonstrates Efficacy in Global Registry

May 4, 2015

Medtronic’s Endurant abdominal aortic aneurysm treatment stent graft system has demonstrated positive results in patients with short and standard neck lengths enrolled in the Engage global registry, the Ireland-based devicemaker announced last week. The registry is the largest single-company database for stent grafts in clinical practice.

Neck length refers to healthy aortic tissue between the top of the aneurysm and the lowest renal artery, delineating the availability of landing zone area for a stent graft proximal end. Neck lengths are the most limiting factor in patient eligibility for standard endovascular repair of abdominal aortic aneurysms, the company says.

Importantly, the Engage registry shows that patients with both short and standard necks can be treated with the Endurant system, the devicemaker says. The registry included 1,237 patients at 79 sits in 30 countries.

The company claims 99.4 percent of standard neck patients and 100 percent of short neck patients enjoyed successful delivery and deployment. Over four years, the two arms displayed similar results in secondary endovascular procedures, ruptures or conversions to open repair rates.

Launched in 2008, the device has treated 200,000 patients worldwide.

Medtronic initiated a clinical study for its Endurant Evo AAA system last week. — Jason Scott